Macrophage migration inhibitory factor (MIF) has been defined as a novel oncogene. Our previous results have shown that MIF may contribute to the progression of neuroblastoma by (a) inducing N-Myc expression and (b) upregulating the expression of angiogenic factors. The aim of this study was to test whether tumor growth could be inhibited by reduction of endogenous MIF expression in neuroblastoma and clarify the molecular mechanisms underlying MIF reduction on the control of neuroblastoma growth. We established human neuroblastoma cell lines stably expressing antisense MIF (AS-MIF) cDNA. These stable transfectants were characterized by cell proliferation, gene expression profile, tumorigenicity and metastasis in vitro and in vivo. Decreased MIF expression was observed after transfection with AS-MIF in neuroblastoma cells and downregulation of MIF expression significantly correlated with decreased expression of NMyc, Ras, c-Met and TrkB at protein level. Affymetrix microarray analysis revealed that expression of IL-8 and c-met was inhibited and neuroblastoma-favorable genes such as EPHB6 and BLU were upregulated in MIF reduced cells. Neuroblastoma cell growth exhibited a nearly 80% reduction in AS-MIF transfectants in vitro. Furthermore, mice in which tumors formed after subcutaneous injection of AS-MIF transfectants showed a 90% reduction in tumor growth compared to control. Metastasis in mice was also suppressed dramatically. Our data demonstrate that targeting MIF expression is a promising therapeutic strategy in human neuroblastoma therapy, and also identifies the MIF target genes for further study.
Introduction
Neuroblastoma is one of the most common malignant tumors in children, and is responsible for about 15% of all pediatric cancer deaths (Maris and Matthay, 1999) . Spontaneous regressions and differentiation in vivo are common in infants and in early-stage tumors, whereas children who are over 1 year of age at clinical presentation often have metastatic disease that fails to respond to medical intervention (Pritchard and Hickman, 1994) . The underlying biological mechanism has not been fully elucidated. Despite recent advances in the management of the disease by conventional chemotherapy, the development of new therapeutic strategies is critically important.
The biological hallmark of neuroblastomas is the complexity of the genetic abnormalities acquired by the tumor cells. Some of these abnormalities are powerful prognostic markers that are independent of the clinical features. These genetic aberrations are ploidy changes, deletions of chromosome arms 1p and 11q, gains of chromosome arm 17q and amplification of the N-myc oncogene, (Bown, 2001) . Overexpression of the N-MYC nuclear phosphoprotein is associated with advanced disease stage, rapid tumor progression and poor prognosis (Bown, 2001; Brodeur, 2003) . Furthermore, expression of TrkB in human neuroblastoma is an important prognostic factor (Nakagawara et al., 1993; Brodeur, 2003) and associated with N-Myc expression (Edsjo et al., 2003) . Despite intensive investigations, the fundamental role of these features in neuroblastoma initiation and progression remains obscure.
The effects of macrophage migration inhibitory factor (MIF) on the proinflammatory and immune responses have been known for some time, but it has also recently begun to be recognized as a protumorigenic factor (Mitchell and Bucala, 2000) . Overexpression of MIF has been identified in prostatic lymph node metastases (Meyer-Siegler and Hudson, 1996) , human melanomas (Shimizu et al., 1999) , breast carcinomas (Bini et al., 1997) , adenocarcinomas of the lung (Kamimura et al., 2000) , bladder cancer (Meyer-Siegler et al., 2004) and hepatocellular carcinomas (Akbar et al., 2001; Ren et al., 2003a) . It has been shown that high levels of MIF significantly correlate with an unfavorable outcome in esophageal squamous cell carcinoma (Ren et al., 2005) and hepatocellular carcinoma (Ren et al., 2003a) and other tumors (del Vecchio et al., 2000; Meyer-Siegler, 2000; Tomiyasu et al., 2000) . Our previous results revealed that MIF was highly expressed in neuroblastoma, and can stimulate oncogene N-myc expression and upregulate the expression of angiogenic factors . MIF is also able to regulate the expression of genes related to tumor cell proliferation, migration and antiapoptosis (Fan et al., 2004) . These results suggest that MIF may play an important role in the development of neuroblastoma.
The aim of this study was to elucidate the mechanism of MIF in tumor development by investigating whether reduction of MIF expression could control tumor proliferation and tumorigenicity in neuroblastoma. We transfected neuroblastoma cells with antisense (AS)-MIF, and the properties of the AS-MIF-transfected clones were compared to those of control cells (transfected with empty vector).
Results

MIF expression in cells transfected with AS-MIF vector
Human neuroblastoma cell line SK-N-DZ, which expressed high level of MIF , were transfected with control vector (vector alone) and AS-MIF vector. After hygromycin selection, 20 clones were picked, passaged and collected. MIF expression in these AS-MIF transfectants was further detected by Western blot analysis. Three representative clones named no. 3, no. 5 and no. 24 were used in this study. The result showed that the amount of MIF was substantially reduced in three clones compared to control cells (empty vector transfection; Figure 1 ).
Effects of AS-MIF transfection on expression of N-Myc, c-met, EPHB6 and other genes To better understand the molecular mechanism of MIF in the development of neuroblastoma, that is, whether MIF blockade can affect the production of molecules related to neuroblastoma development, Affymetrix microarray and Western blot analysis were applied to identify genes or proteins whose expression was altered in AS-MIF-transfected cells. Western blot showed that AS-MIF transfection significantly inhibited N-Myc expression compared to control vector-transfected cells (Figure 1) . Furthermore, Affymetrix microarray showed that of a total of about 22 283 probe sets, there were 44 genes changed in three clones transfected with AS-MIF more than twofold with P-value less than 0.001. The genes found to be up-or downregulated are selected in Table 1 . The most interesting genes were c-met, EPHB6, Visinin-like protein-1 (VSNL1), BLU, Ras and interleukin-8 (IL-8). Table 1 showed that the average change of these genes was significantly different than in the control cells. The expression levels of c-met, EPHB6, VSNL-1, Ras and BLU were confirmed by real-time RT-PCR (Table 1) . IL-8 expression was confirmed by detection of IL-8 in the supernatants of cell culture using enzyme-linked immunosorbent assay (ELISA) (Figure 2 ). In addition, Western blot analysis revealed that expression of TrkB, c-Met and Ras was markedly inhibited in clone no. 3, no. 5 and no. 24 compared to cells transfected with vector alone (Figure 3 ). The phosphorylation of TrkB and c-Met was also reduced in these clones (Figure 3) .
Affymetrix microarray and real-time RT-PCR data showed that oncogene c-met mRNA was suppressed in (Figure 4 ). Furthermore, there was a significant positive correlation between expression of MIF and c-Met (r ¼ 0.635, P ¼ 0.002).
Effect of AS-MIF on cell growth in vitro
To detect whether the reduction of MIF expression affects neuroblastoma cell growth in vitro, cells were cultured in Dulbecco's minimum essential medium (DMEM) with 10% fetal bovine serum (FBS) for 3 days, and proliferation was determined by 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay. As shown in Figure 5 , the proliferation rates of clone no. 3, no. 5 and no. 24 were suppressed significantly to 60.3, 52.5 and 78.4%, respectively, compared with those of the cells transfected with vector alone.
Effect of AS-MIF on cell apoptosis
To detect whether the reduction of MIF expression can induce neuroblastoma cell apoptosis, cells were cultured in DMEM with 2% FBS for 48 h and the spontaneous apoptosis was detected by Annexin V binding assay. As shown in Figure 6 , numbers of cells from clone no. 3, no. 5 and no. 24 that were undergoing spontaneous apoptosis were significantly higher compared to cells transfected with vector alone. Targeting MIF in human neuroblastoma Y Ren et al
Effect of AS-MIF on cell invasiveness in vitro
The invasiveness of AS-MIF transfectants was evaluated using an in vitro invasion assay. We found that cell numbers of clone no. 3, no. 5 and no. 24 that penetrated the Matrigel were significantly reduced to those of neuroblastoma cells transfected with vector alone (Po0.001; Figure 7 ).
Effects of AS-MIF transfection on tumor growth and metastasis in vivo
Given these findings in vitro, we further analysed the effect of suppressing MIF expression on tumor growth and metastasis in athymic nude mice. For a tumor growth mouse xenograft model, mice were inoculated subcutaneously with 1 Â 10 6 cells. Empty vector-transfected neuroblastoma cells formed progressively, growing solid tumors in all mice (n ¼ 10; Figure 8 ). By contrast, clone no. 3, no. 5 and no. 24 produced much smaller tumors (n ¼ 10 for each clone; Figure 8 ). We further investigated the metastatic potential of AS-MIF transfectants. Nude mice were injected intravenously with 2 Â 10 6 neuroblastoma cells transfected with vector alone or clone no. 3, no. 5 and no. 25 (n ¼ 10 for each clone and control). After 2-3 months of the injection, 70% mice in control group developed lung metastasis (Figure 9a ), whereas only 10-20% mice developed lung metastasis in AS-MIF-transfected groups (Table 2) . Histological examination indicated tumor cells in the lung (Figure 9b ).
Effects of AS-MIF transfection on formation of capillary vessels
Angiogenesis is required for the growth, expansion and metastasis of tumors. We therefore observed the angiogenesis of tumors derived from the AS-MIF transfectants (n ¼ 10 for each clone) and cells transfected with vector alone (n ¼ 10). The tumors derived from AS-MIF transfectants had a lower microvessel density (MVD) than those from the control cells. The tumor MVD in tumors derived from AS-MIF group (n ¼ 30) was 12.371.5/high-power field (HPF) and 47.974.8/ HPF of the control cells (n ¼ 10). Targeting MIF in human neuroblastoma Y Ren et al
Discussion
Overexpression of MIF is frequently observed in a number of different primary carcinomas. However, little is known about the functional role of MIF in the pathogenesis and progression of neuroblastoma. Our previous research has shown that human neuroblastoma expresses high levels of MIF, and the overexpression of MIF significantly correlates with tumor grade and NMyc expression . To assay a possible functional relationship between MIF expression and tumorigenicity in neuroblastoma, SK-N-DZ neuroblastoma cells were transfected with an AS-MIF expression vector, and a decrease in MIF expression in neuroblastoma cells was observed after transfection. Our data revealed that c-Met, N-Myc, TrkB, Ras and IL-8 were inhibited and neuroblastoma favorable genes such as EPHB6 and BLU were upregulated in MIF reduced cells. We demonstrated that downregulation of MIF expression can result in a reduction in cell proliferation and tumor growth and metastasis in vitro and in nude mice. It has been reported that MIF is able to enhance tumor cell growth (Nishihira et al., 2003) . Several studies have also shown that reduction of MIF results in the inhibition of tumor cell proliferation in bladder cancer (Meyer-Siegler et al., 2004) , melanoma (Shimizu et al., 1999) and colon cancer (Sasaki et al., 2002) . However, the molecular mechanisms are poorly understood. We have previously demonstrated that MIF was highly expressed in neuroblastoma cells and that its expression is significantly correlated with cell differentiation, suggesting the involvement of MIF in neuroblastoma cell proliferation and differentiation. Consistent with these findings, we have now established that AS-MIF transfection markedly suppresses neuroblastoma growth and metastasis in vitro and in vivo. We further investigated the possible mechanism for this phenomenon. We first showed that expression of NMyc, c-Met, TrkB, Ras and IL-8 levels were decreased, and EPHB6 and BLU levels increased, in AS-MIF transfectants. It has been shown that N-myc amplification is associated with advanced disease stage, rapid tumor progression and poor prognosis in neuroblastoma (Seeger et al., 1988 (Seeger et al., , 1985 . N-myc is associated with tumorigenesis and cell proliferation (Chambery et al., 1999) . In our previous study, we observed that MIF could stimulate expression of both N-myc mRNA and N-Myc protein in neuroblastoma cells . C-met has been identified as an activated oncogene (Park et al., 1986) . A large number of studies have shown that c-Met is frequently expressed in carcinomas and in other types of human solid tumors and their metastases. Overexpression of c-Met is often associated with poor prognosis (Birchmeier et al., 2003) . Highly invasive neuroblastoma cells express c-Met and the presence of paracrine HGF/c-met signaling was associated with increased neuroblatoma invasiveness in vitro and in vivo (Hecht et al., 2004) . The recent study showed that TrkB cooperated with c-Met-enhanced neuroblastoma invasiveness (Hecht et al., 2005) . In the present study, our data showed that the expression of c-Met and TrkB was decreased in MIF reduced cells and MIF expression significantly correlated with c-Met protein expression in human neuroblastoma specimens. This strongly indicates that MIF may have a function in upregulating c-Met or TrkB expression. EPHB6 is a favorable neuroblastoma gene, which is downregulated (Tang et al., 2000 (Tang et al., , 2004 Hafner et al., 2003; Fox and Kandpal, 2004) . Highlevel expression of EPHB6 predicts favorable neuroblastoma outcome, and forced expression of these genes inhibits growth of unfavorable neuroblastoma cells (Tang et al., 2000) . However, it is not clear how EPHB6 is regulated. A particularly significant finding of this study was that EPHB6 was increased in MIF reduced neuroblastoma cells. This result suggests a promising direction for the further study of the relationship between MIF and EPHB6. VSNL-1 is expressed in the central nervous system, where it plays a crucial role in regulating cAMP levels, cell signaling and differentiation. High-level VSNL-1 expression is also associated with less aggressive and high-grade squamous cell carcinoma (Mahloogi et al., 2003) . This indicates that VSNL-1 may play an important role in regulating tumor cell invasiveness, and that its loss could aid in enhancing the advanced malignant phenotype. BLU is abundantly expressed in normal lung tissue. However, its expression is drastically reduced in a subset of lung tumor cell lines (Agathanggelou et al., 2003) . BLU is also inactivated in neuroblastoma. Methylation of the BLU promoter region (inactivation of BLU) in neuroblastoma inversely correlates with tumor stage (Agathanggelou et al., 2003) . These data suggest that BLU is one of the candidate tumor suppressor genes. Taken together, we found a number of genes or proteins whose expression levels were markedly modified by MIF. We suggest that these genes may be involved in the MIF-induced tumor growth inhibition. Angiogenesis is a critical process in the development and metastasis of many solid tumors, including neuroblastoma. It has been reported that the vascularity of neuroblastoma in patients with widely metastatic disease is significantly higher than that in patients with local or regional disease, and that vascularity shows a strong inverse correlation with the survival of patients (Meitar et al., 1996) . One of the important activities of MIF in promoting tumorigenesis and metastasis is to stimulate angiogenesis (Ogawa et al., 2000) . Recent studies have shown that immunoneutralization of MIF during the initial stage of lymphoma growth has profound effects on tumor size (Chesney et al., 1999) , and that MIF is a required factor for tumor-initiated endothelial cell proliferation (Yang et al., 2000) . This indicates that MIF may function to stimulate tumor-associated angiogenesis by a direct effect on endothelial growth. However, the role of MIF in angiogenesis involving tumor and endothelial cells is less well understood. IL-8 has been identified as an angiogenesis-regulating molecule that induces angiogenesis (Koch et al., 1992; Desbaillets et al., 1997) . The expression of IL-8 has been found in various human cancers (Xie, 2001) . Recent studies have also demonstrated that IL-8 regulates tumor cell growth and metastasis in many tumors such as melanoma, carcinoma of breast, stomach, pancreas and liver. Our previous results indicated that serum IL-8 from patients with hepatocellular carcinoma significantly correlated with tumor size, tumor stage and venous invasion (Ren et al., 2003b) , suggesting that IL-8 may be directly or indirectly involved in tumor progression. We have also demonstrated that MIF is able to stimulate neuroblastoma cells to express IL-8 . This study has demonstrated that IL-8 gene expression is drastically decreased in MIF reduced cells (>13-fold), and an ELISA assay has confirmed that the volume of IL-8 protein produced by MIF reduced cells was 10 times lower than in the control cells. In addition, amplification of N-myc is associated with enhanced angiogenesis of human neuroblastoma (Meitar et al., 1996) . It has recently been reported that enhanced expression of N-myc in human neuroblastoma cells downregulates an inhibitor of endothelial cell proliferation, activin A. We have shown in this study that MVD in tumors derived from AS-MIF transfectants was significantly lower than in the control tumors. Overall, the study's findings provide evidence that AS-MIF treatment may exert its antiangiogenic effects via suppression of IL-8 and N-Myc.
In conclusion, we have demonstrated that blocking MIF expression would benefit tumor control in neuroblastoma by inhibiting tumor growth, angiogenesis and metastasis. With this approach, we have shown that reduction of MIF results in tumor growth inhibition, and that suppression may be achieved by inhibiting NMyc, IL-8, c-Met and TrkB. On the other hand, increasing the expression of tumor suppressor genes (BLU, VISNL-1) and neuroblastoma favorite gene (EPHB6) may also contribute to tumor reduction. Therefore, these genes could potentially be key players in the development of neuroblastoma. Our data not only demonstrate that targeting MIF expression is a promising therapeutic strategy for human neuroblastoma therapy but also identify the MIF target genes for further study.
Materials and methods
Cells
Human neuroblastoma cell line SK-N-DZ was obtained from American Type Culture Collection (ATCC; Rockville, MD, USA). Cells were maintained in DMEM supplemented with 10% FBS (Gibco BRL-life Technologies, Grand Island, NY, USA) and 1% penicillin-streptomycin in a humidified incubator (95% air and 5% CO 2 ) at 371C.
Tissue samples
Tumor specimens were obtained from 21 patients with surgically resected primary neuroblastoma treated between 1990 and 2000 in Queen Mary Hospital, Hong Kong. The patients included 16 males and five females, and their median age at diagnosis was 60 months (range: 6.0-240 months). Representative blocks from both tumorous and non-tumorous tissues from each specimen were taken for immunohistochemical study. , and stable clones were selected by resistance to hygromycin (300 mg/ml; Geneticin-Life Technologies, Gaithersburg, MD, USA) and expanded into cell lines. Three clones (no. 3, no. 5 and no. 24) transfected with MIF AS-expressing vectors were analysed for MIF expression by Western blot. All three clones showed low levels of MIF expression (Figure 1) . The cells transfected with empty vector were used as a control.
Construction of expression vectors and transfection of neuroblastoma cells
RNA isolation and application to Affymetrix GeneChip
Total RNA samples were prepared from cell culture with the TRIzol reagent (Invitrogen) according to the manufacturer's directions. Probe synthesis and hybridization of human U-133A GeneChip Oligo Microarrays (Affymetrix, Santa Clara, CA, USA) were performed in accordance with the manufacturer's instructions. Gene expression data (CHP file of Affymetrix Microarray Suite 5.0 software) were normalized to a global target intensity of 500.
Real-time quantitative RT-PCR Total RNA (0.5 mg) was used to generate cDNA using the Taqman Reverse Reagents (Applied Biosystems, Foster City, CA, USA). Taqman Universal PCR Master Mix and Taqman Gene Expression Assays, which contain the primers for candidate genes (TDO2, FGF5, Met, VSNL-1, EPHB6, COL6A3, Intergrin and Blu; Applied Biosystems, Foster City, California), were performed for detecting RT-PCR products. Pre-normalized primers for 18S ribosomal RNA were obtained from Applied Biosystems (Foster City, CA, USA). The PCR cycling conditions were performed for all of the samples, as follows: 2 min at 501C for incubation; 10 min at 951C for AmpliTaq amplification and 40 cycles for the melting (951C for 15 s) and annealing/extension (601C for 1 min) steps. PCR reactions for each template were performed in triplicate in one 96-well dish per gene-specific primer pair tested. The comparative C T method (Livak and Schmittgen, 2001 ) was used to quantitate the expression for each gene.
Western blot analysis
Cells were washed with phosphate-buffered saline (PBS), and directly lysed in RIPA buffer (0.5% sodium deoxycholate, 0.1% sodium dodecyl sulfate (SDS), 1% NP-40 and PBS) with PMSF and proteases inhibitors. Protein concentration was determined by Bio-Rad DC assay (Bio-Rad, Hercules, CA, USA). The samples were adjusted to equal protein concentrations and subjected to SDS-polyacrylamide gel electrophoresis (SDS-PAGE). Proteins on the gel were transferred onto nitrocellulose membranes blocked with 5% bovine serum albumin in Tris-buffered saline containing 0.1% Tween-20 for 1 h at room temperature. The membranes were then incubated with the indicated primary antibodies overnight at 41C, washed with PBS and incubated with the appropriate secondary antibody. The immunoreactive bands were visualized with chemiluminescence (ECL, Amersham, UK).
Double immunohistochemical staining
Paraffin sections were incubated with primary c-Met monoclonal antibody (mAb) overnight at 41C. Sections were then washed with PBS (pH 7.4). Endogenous peroxidase was inactivated with 3% H 2 O 2 in methanol, and then incubated with goat anti-mouse IgG-FITC (Sigma, St Louis, MO, USA) for 2 h at room temperature. Sections were then mounted with medium for fluorescence with DAPI (Vector Laboratories, Burlingame, CA, USA). Electronic images of the immunofluorescence visualized under a fluorescence microscope (Nikon eclipse E600, Japan) were saved to PC. The sections were then washed with PBS. After microwave heating, antibody against MIF was applied as primary antibody at 41C overnight on same sections, and sections were then incubated with anti-mouse universal immunoalkalinephosphatase polymer (Nichirei Corporation, Tokyo, Japan) for 2 h at room temperature. The color was subsequently developed with fast red substrate system (Sigma). Sections were mounted with same mounting medium above. The same fields as in the immunofluorescence images were subsequently selected and visualized under the same microscope and also saved as electronic images for comparison and analysis of colocalization.
Cell proliferation assay Cells (1 Â 10 4 ) were placed in each well of a 96-well plate and cultured in DMEM with 10% FBS for 72 h. The cell proliferation was examined by MTT colorimetric assay in the formazan product and MTT was measured as absorbance at 550 and 650 nm. In vitro invasion assay Tumor cell invasion and migration were assayed in the invasion chamber (Becton Dickinson Labware) with 8 mmporosity polycaronate filter membrane. The upper sides of the membranes were precoated with Matrigel matrix (Becton Dickinson Labware; 30 mg/insert). The coated insert was placed in each well of a 24-well plate filled with 500 ml of medium (MEM with 1% FCS). The upper well contained tumor cell suspension (200 ml, 1 Â 10 4 cell/ml medium). The cells in the chambers were incubated for 24 h at 371C, and migration to the underside of the pre-coated filter was measured. For each chamber, the number of migrated cells in five randomly chosen high-power fields was counted.
Apoptosis assay
Tumor growth in nude mice
The 6-week-old BALB/c nude mice (Laboratory Animal Unit, The University of Hong Kong, Hong Kong, SAR, China) were injected subcutaneously with 2 Â 10 6 SK-N-DZ transfected with vector alone (control cell line, n ¼ 10) or AS-MIFtransfected cells lines (no. 3, no. 5 and no. 24; n ¼ 10 for each cell line). Tumor growth in each group was monitored everyday by two-dimensional measurements of individual tumors from each mouse.
Tumor metastasis in nude mice
The 6-week-old BALB/c nude mice were injected intravenously with 2 Â 10 6 SK-N-DZ transfected with vector alone or AS-MIF-transfected cells (n ¼ 10). All mice were monitored on a weekly basis for bodyweight and other abnormalities. Once
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Evaluation of MVD
Tissue sections were immunostained with human CD34 mAb and scanned by light microscopy at low-power field ( Â 40) and the vessel count in areas with the highest number of capillaries was assessed at HPF ( Â 200). The average counts of five fields were determined. The MVD was counted by two neutral investigators without specialized knowledge of MIF and neuroblastoma.
Statistical analysis
Differences between means were analysed by Student's t-test. Pearson's correlation was used to analyse the correlation between MIF and c-Met expression. Differences were considered significant when the P-value was less than 0.05. Data are presented as mean7s.d. Affymetrix gene expression was normalized and analysed by a semilinear in-slide model and a modified t-test described previously (Fan et al., 2004) .
